(Q43676400)

English

A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial

scientific article published in July 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial (English)

1 reference

Europe PubMed Central

25 November 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

author name string

Lauer SJ

1

1 reference

Europe PubMed Central

25 November 2017

Shuster JJ

2

1 reference

Europe PubMed Central

25 November 2017

Mahoney DH Jr

3

1 reference

Europe PubMed Central

25 November 2017

Winick N

4

1 reference

Europe PubMed Central

25 November 2017

Toledano S

5

1 reference

Europe PubMed Central

25 November 2017

Munoz L

6

1 reference

Europe PubMed Central

25 November 2017

Kiefer G

7

1 reference

Europe PubMed Central

25 November 2017

Pullen JD

8

1 reference

Europe PubMed Central

25 November 2017

Steuber CP

9

1 reference

Europe PubMed Central

25 November 2017

Camitta BM

10

1 reference

Europe PubMed Central

25 November 2017

publication date

1 July 2001

1 reference

Europe PubMed Central

25 November 2017

1 reference

Europe PubMed Central

25 November 2017

15

1 reference

Europe PubMed Central

25 November 2017

7

1 reference

Europe PubMed Central

25 November 2017

1038-1045

1 reference

Europe PubMed Central

25 November 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402132

0 references

Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Medical Research Council Working Party on Childhood Leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of clinical and laboratory features to define prognostic subgroups in B-precursor acute lymphoblastic leukemia: experience of the Pediatric Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of a multidrug-resistance gene in human tumors and tissues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402132

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2402132

1 reference

Europe PubMed Central

25 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

25 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43676400&oldid=2102434797"